 Delcath Systems, Inc. DCTH, an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the closing of its previously announced underwritten public offering of 2.2 million shares of common stock or common stock equivalents and Series F warrants to purchase up to 2.2 million shares of common stock. Delcath received gross proceeds of approximately 22.0 million from the offering, before deducting the underwriting discount and estimated offering expenses. A registration statement relating to the securities being sold in this offering was filed with the Securities and Exchange Commission SEC on January 13, 2020 and was declared effective on April 30, 2020. 